Scienture announces cancellation of ELOC

SCIENTURE (SCNX) HOLDINGS has terminated its Equity Line of Credit facility effective as of May 22, 2025. In connection with cancellation of the ELOC, on June 16, 2025, the Company filed a post-effective amendment to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on December 3, 2025, declared effective on February 14, 2025. The post-effective amendment deregisters all 310,488 unsold shares of the Company’s common stock that had been registered under the registration statement. This strategic financial decision comes as the Company prepares to commercially launch its first FDA-approved product candidate, Arbli, which is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market. The Company continues to expect that it will commercially launch Arbli by making it available to patients in the U.S. during Q3 2025. Arbli is indicated for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy, and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.